Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search


318 items
9:52 AM, Oct 19, 2018  |  BC Extra | Preclinical News

Study uncovers large batch effects in TCGA exome sequencing data

A preprint article published in bioRxiv identified large cross-institutional batch effects for a subset of The Cancer Genome Atlas data. The report provides a warning to all multisite sequencing consortia, and calls for re-examining results...
3:07 PM, Oct 18, 2018  |  BC Extra | Preclinical News

UC Berkeley group identifies new Cas enzyme

In a Science paper published Thursday, Jennifer Doudna's lab reported a new family of CRISPR-associated Cas enzymes, CRISPR-associated 14 (Cas14), that could improve CRISPR-based diagnostics. The team described a family of Cas14 variants isolated from...
9:50 AM, Oct 18, 2018  |  BC Extra | Preclinical News

Flurry of news highlights latest in switch-controlled gene therapy

A series of company announcements signal advances in switch-controlled gene therapy. uniQure N.V. (NASDAQ:QURE) and partner Synpromics Ltd. (Edinburgh, U.K.) announced preclinical data on Thursday on a liver-directed gene therapy system at the European Society of...
3:51 PM, Oct 17, 2018  |  BC Extra | Preclinical News

Immune-Onc, University of Texas discover new AML target

A study published Wednesday in Nature revealed a checkpoint inhibitor target for acute myelogenous leukemia, adding a new mechanism of action for an indication that, until recently, has been a new drug wasteland. Immune-Onc Therapeutics...
2:19 PM, Oct 15, 2018  |  BC Extra | Preclinical News

mAb blocks fibrin's inflammation without clotting interference to treat MS, Alzheimer's

Gladstone Institutes researchers developed a mAb that could help treat neurodegenerative and autoimmune CNS diseases such as multiple sclerosis or Alzheimer's disease by specifically blocking the proinflammatory effects of fibrin without compromising its clotting ability. In...
2:00 PM, Oct 12, 2018  |  BC Extra | Preclinical News

Gene editing creates offspring from same-sex parents

Chinese researchers showed it may be possible to create viable offspring from same-sex parents, pushing the limits of gene editing embryo research and proving that unresolved ethical issues have not halted progress. In a paper published...
11:33 AM, Oct 10, 2018  |  BC Extra | Preclinical News

Quentis links ER stress, mitochondrial dysfunction with antitumor T cell activity

Researchers at Quentis Therapeutics Inc. (New York, N.Y.), Weill Cornell Medicine and Dana-Farber Cancer Institute uncovered a new mechanism of tumor immune evasion in which endoplasmic reticulum stress limits mitochondrial respiration and antitumor activity in...
5:12 PM, Oct 09, 2018  |  BC Extra | Preclinical News

In utero base editing corrects metabolic birth defect

Researchers from Children's Hospital of Philadelphia and University of Pennsylvania opened the door to prenatal genome editing by using a relatively new CRISPR-based approach called base editor 3 to correct tyrosinemia type I, a rare...
3:38 PM, Oct 08, 2018  |  BC Extra | Preclinical News

Tokyo team IDs monocyte subtype for inflammation recovery, repair

Tokyo University of Pharmacy and Life Sciences researchers identified a subpopulation of immunoregulatory monocytes that can resolve systemic inflammation and promote tissue repair, suggesting the monocyte subset could be targeted to treat inflammatory diseases such...
2:52 PM, Oct 05, 2018  |  BC Extra | Preclinical News

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

Selecta Biosciences Inc. (NASDAQ:SELB) showed its SVP-Rapamycin nanoparticles co-administered with an adeno-associated viral (AAV) vector-mediated transgene could enable repeat dosing of a gene therapy by suppressing the host’s immune response against the viral vector in...